Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Carol Stiff

- PMLiVE

InflaRx seeks FDA authorisation for vilobelimab for critically ill COVID-19 patients

A phase 3 study showed that the antibody reduced the all-cause mortality rate after 28 days

Modern Medical Affairs: How to Leverage Tech and Data as an MSL

Dr. Luca Dezzani, VP of US Oncology Medical Affairs at Johnson & Johnson, explores innovation in Medical Affairs, new technologies for data dissemination and medical education, how to engage with...

Impetus Digital

- PMLiVE

Shionogi’s antiviral COVID-19 treatment meets phase 3 primary endpoint

Ensitrelvir reduced the time taken to resolve five key symptoms

- PMLiVE

WHO reports warnings of ‘COVID-19 complacency’ from countries tracking global vaccine roll-out

Vaccination rates in low-income countries stand at 19% compared to almost 75% in high-income countries

- PMLiVE

Pfizer and BioNTech seek FDA authorisation for COVID-19 booster for children

An application will also be submitted to the European Medicines Agency to extend the marketing authorisation for this age group

- PMLiVE

COVID-19 linked to long-term neurologic disorders in new US study

Those infected with the virus had a 77% higher risk of developing memory problems versus control groups

- PMLiVE

Valneva actively discussing second-generation COVID-19 vaccine with prospective partner

The company also plans to send the remaining stocks of its current COVID-19 vaccine to international markets

- PMLiVE

Pfizer to supply 6 million Paxlovid treatments to low- and middle-income countries

Eligible countries will be offered treatment courses according to Pfizer’s tiered pricing approach

Leveraging the Cloud for Patient-friendly Medical Devices

Robert Kaul, Founder, CEO & President of Cloud DX, explores connected health, remote patient monitoring, telemedicine, and more. He also shares his tips for new entrepreneurs based on his 17...

Impetus Digital

- PMLiVE

AstraZeneca’s COVID-19 treatment granted EC approval

Evusheld significantly reduced risk of severe COVID-19 or death in a phase 3 trial

- PMLiVE

AstraZeneca’s COVID-19 treatment receives CHMP recommendation for use in EU

Evusheld provided statistically significant protection against progression to severe COVID-19 or death

- PMLiVE

Gilead’s Veklury WHO recommendation expanded for treatment of severe COVID-19

The antiviral showed a 17% lower relative risk of death or progression compared to standard of care

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links